AGIO — Agios Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.21bn
- $1.59bn
- $54.03m
U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune
Brief: Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes
U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios
Agios scraps blood cancer drug program after study setback (updated)
Agios falls after scrapping blood disorder drug program
Agios scraps blood disorder drug program after study miss
Brief: Avanzanite Bioscience’S Partner Agios Announces Pyrukynd® (Mitapivat) Approval In EU
Brief: Agios’ Pyrukynd® (Mitapivat) Approved In The European Union For Adults With Thalassemia
Biopharma firm Agios Q1 product revenue more than doubles, beats estimates
Brief: Agios Pharmaceuticals Q1 Product Revenue USD 20.746 Million Vs. IBES Estimate USD 13.6 Million
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
Agios falls after Novo's sickle cell disease drug shows promise in late-stage study
Agios falls after Novo's sickle cell disease drug shows promise in late-stage study
Brief: Agios’ Pyrukynd® (Mitapivat) Approved For Adults With Thalassemia In The United Arab Emirates
Agios 2025 product revenue beats analyst estimates
Brief: Agios Pharmaceuticals FY Product Revenue USD 54.028 Million Vs. IBES Estimate USD 45.7 Million
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure